Antengene to Present Preclinical Data for ATG-207 at ACR 2026

Antengene Corporation Limited, a global biotechnology company, announced it will present new preclinical data on its candidate drug, ATG-207 (αCD3-TGF-β), at the upcoming American College of Rheumatology (ACR) 2026 meeting. The presentation will focus on the findings from preclinical studies of this bifunctional fusion protein.

ATG-207 is designed to simultaneously target T-cells and the TGF-β signaling pathway, representing a novel approach for the treatment of autoimmune and inflammatory diseases. The company aims to develop first-in-class and best-in-class medicines for challenging medical conditions.

Details of the specific preclinical results to be presented have not yet been disclosed. The ACR meeting serves as a significant forum for rheumatology professionals and researchers to share advancements in the field.

The presentation is part of Antengene's ongoing efforts to advance its drug development pipeline, which focuses on discovering, developing, and commercializing innovative therapies. The company is committed to addressing unmet medical needs through its research and development initiatives.